Marius Ahm Stauning

Marius Ahm Stauning

Auto-generated profile, based on publicly available information

Marius Ahm Stauning

Department of Clinical Microbiology, Centre of Diagnostic Investigation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
TATariq U. Azam
Tariq U. Azam
HSHusam R. Shadid
Husam R. Shadid
PBPennelope Blakely
Pennelope Blakely
POPatrick O’hayer
Patrick O’hayer
HBHanna Berlin
Hanna Berlin
ICInternational Study of Inflammation in COVID-19
International Study of Inflammation in COVID-19
Significance Statement: Nearly half of hospitalized patients with coronavirus disease 2019 (COVID-19) develop AKI, with 20% requiring dialysis. High levels of soluble urokinase plasminogen activator receptor (suPAR)—an immune mediator of kidney injury—predispose patients to AKI in various clinical scenarios, including critical illness. High suPAR levels modulate mitochondrial respiration and induce the generation of reactive oxygen species in proximal tubular cells, sensitizing them to additional insults. In a multicenter observational study, the authors measured plasma suPAR in 352 patients with COVID-19 within 48 hours of their hospitalization. They found suPAR levels to be strongly associated with incident AKI, independent of such clinical characteristics as kidney function and inflammatory biomarkers, and predictive of the need for dialysis. SuPAR may be a key component of the pathophysiology of AKI in COVID-19. Background: AKI commonly occurs in patients with coronavirus disease 2019 (COVID-19). Its pathogenesis is poorly understood. The urokinase receptor system is a key regulator of the intersection between inflammation, immunity, and coagulation, and soluble urokinase plasminogen activator receptor (suPAR) has been identified as an immunologic risk factor for AKI. Whether suPAR is associated with COVID-19–related AKI is unknown. Methods: In a multinational observational study of adult patients hospitalized for COVID-19, we measured suPAR levels in plasma samples from 352 adult patients that had been collected within 48 hours of admission. We examined the association between suPAR levels and incident in-hospital AKI. Results: Of the 352 patients (57.4% were male, 13.9% were black, and mean age was 61 years), 91 (25.9%) developed AKI during their hospitalization, of whom 25 (27.4%) required dialysis. The median suPAR level was 5.61 ng/ml. AKI incidence rose with increasing suPAR tertiles, from a 6.0% incidence in patients with suPAR 6.86 ng/ml (third tertile). None of the patients with suPAR <4.60 ng/ml required dialysis during their hospitalization. In multivariable analysis, the highest suPAR tertile was associated with a 9.15-fold increase in the odds of AKI (95% confidence interval [95% CI], 3.64 to 22.93) and a 22.86-fold increase in the odds of requiring dialysis (95% CI, 2.77 to 188.75). The association was independent of inflammatory markers and persisted across subgroups. Conclusions: Admission suPAR levels in patients hospitalized for COVID-19 are predictive of in-hospital AKI and the need for dialysis. SuPAR may be a key component of the pathophysiology of AKI in COVID-19.

1 July 2018 in Journal of Hospital Infection
Verified
Journal Article
Open access
MSM.T. Stauning
M.T. Stauning
ABA. Bediako-Bowan
A. Bediako-Bowan
LAL.P. Andersen
L.P. Andersen
JOJ.A. Opintan
J.A. Opintan
ALA.-K. Labi
A.-K. Labi
SBS. Bjerrum
S. Bjerrum
Current literature examining the relationship between door-opening rate, number of people present, and microbial air contamination in the operating room is limited. Studies are especially needed from low- and middle-income countries, where the risk of surgical site infections is high. To assess microbial air contamination in operating rooms at a Ghanaian teaching hospital and the association with door-openings and number of people present. Moreover, we aimed to document reasons for door-opening. We conducted active air-sampling using an MAS 100® portable impactor during 124 clean or clean-contaminated elective surgical procedures. The number of people present, door-opening rate and the reasons for each door-opening were recorded by direct observation using pretested structured observation forms. During surgery, the mean number of colony-forming units (cfu) was 328 cfu/m3 air, and 429 (84%) of 510 samples exceeded a recommended level of 180 cfu/m3. Of 6717 door-openings recorded, 77% were considered unnecessary. Levels of cfu/m3 were strongly correlated with the number of people present (P = 0.001) and with the number of door-openings/h (P = 0.02). In empty operating rooms, the mean cfu count was 39 cfu/m3 after 1 h of uninterrupted ventilation and 52 (51%) of 102 samples exceeded a recommended level of 35 cfu/m3. The study revealed high values of intraoperative airborne cfu exceeding recommended levels. Minimizing the number of door-openings and people present during surgery could be an effective strategy to reduce microbial air contamination in low- and middle-income settings.

1 January 2021 in Biomarker Insights
Verified
Journal Article
Open access
PDF file
IAIzzet Altintas
Izzet Altintas
JEJesper Eugen-Olsen
Jesper Eugen-Olsen
SSSanteri Seppälä
Santeri Seppälä
JTJens Tingleff
Jens Tingleff
MSMarius Ahm Stauning
Marius Ahm Stauning
OAOve Andersen
Ove Andersen
Objectives: Elevated soluble urokinase Plasminogen Activator Receptor (suPAR) is a biomarker associated with adverse outcomes. We aimed to investigate the associations between plasma suPAR levels (testing the cut-offs ⩽4, 4-6, and ⩾6 ng/mL) with risk of 14-day mortality, and with the risk of mechanical ventilation in patients that tested positive for SARS-CoV-2. Methods: Observational cohort study of patients presenting with symptoms of COVID-19 at Department of Emergency Medicine, Amager and Hvidovre Hospital, Denmark from March 19th, 2020 to April 3rd, 2020. Plasma suPAR was measured using suPARnostic technologies. Patients were followed for development of mechanical ventilation and mortality for 14 days. Validation of our findings were carried out in a similar sized COVID-19 patient cohort from Mikkeli Central Hospital, Finland. Results: Among 386 patients with symptoms of COVID-19, the median (interquartile range) age was 64 years (46-77), 57% were women, median suPAR was 4.0 ng/mL (2.7-5.9). In total, 35 patients (9.1%) died during the 14 days follow-up. Patients with suPAR ⩽4 ng/mL (N = 196; 50.8%) had a low risk of mortality (N = 2; 1.0%; negative predictive value of 99.0%, specificity 55.3%, sensitivity 95.2%, positive predictive value 17.4%). Among patients with suPAR ⩾6 ng/mL (N = 92; 23.8%), 16 died (17.4%). About 99 patients (25.6%) tested positive for SARS CoV-2 and of those 12 (12.1%) developed need for mechanical ventilation. None of the SARS-CoV-2 positive patients with suPAR ⩽4 ng/mL (N = 28; 38.8%) needed mechanical ventilation or died. The Mikkeli Central Hospital validation cohort confirmed our findings concerning suPAR cut-offs for risk of development of mechanical ventilation and mortality. Conclusions: Patients with symptoms of COVID-19 and suPAR ⩽4 or ⩾6 ng/mL had low or high risk, respectively, concerning the need for mechanical ventilation or mortality. We suggest cut-offs for identification of risk groups in patients presenting to the ED with symptoms of or confirmed COVID-19.

24 April 2017 in Physical Review X
Verified
Journal Article
Open access
PDF file
RBRune W. Berg
Rune W. Berg
MSMarius Tving Stauning
Marius Tving Stauning
JSJakob Balslev Sørensen
Jakob Balslev Sørensen
HJHenrik Jahnsen
Henrik Jahnsen
The action potential (AP) is an electrical impulse elicited by depolarization of the neuronal membrane from the resting membrane potential (around −70  mV). It propagates along the axon, allowing for rapid and distant communication. Recently, it was claimed that two APs traveling in opposite direction will pass unhindered through each other (penetrate) upon collision [Gonzalez-Perez et al. Phys. Rev. X 4, 031047 (2014)]. We tested this claim under carefully controlled conditions and found that we cannot reproduce penetration. Instead, APs consistently annihilated upon collision. This is consistent with a vast body of literature.

29 June 2026 in Malaria Journal
Verified
Journal Article
Open access
MSMarius Ahm Stauning
Marius Ahm Stauning
MRMadalena Raposo
Madalena Raposo
NMNono Mvuama
Nono Mvuama
BMBaudouin Matela
Baudouin Matela
ATAntoinette Tshefu
Antoinette Tshefu
HHHelle Hansson
Helle Hansson
Artemisinin-based combination therapies (ACTs) are the cornerstone of Plasmodium falciparum malaria treatment. Recent reports have documented P. falciparum with mutations associated with artemisinin partial resistance in eastern DRC, raising concerns about reduced drug susceptibility. This study examines the prevalence of mutations linked to reduced ACT efficacy in P. falciparum isolates collected December 2024-February 2025 in the Kongo Central Province, western DRC. Dried blood spots were obtained from children under two years of age attending targeted health facilities and testing positive for malaria with rapid diagnostic tests. Diagnosis was confirmed with qPCR and Illumina-targeted amplicon sequencing was used to analyse mutations in the pfk13, pfubp-1, pfcoronin, pfmdr-1 and pfcrt genes. Pfk13 Q613E classified by WHO as potential marker of artemisinin partial resistance was found in a single sample, while pfubp-1 mutations D1525E and E1528D, also suspected of being linked to artemisinin partial resistance were found in 20% and 22% of the sequencing positive samples, respectively. N-Y-S-N-D and N-F-S-N-D were the dominating pfmdr1 haplotypes while the pfcrt wildtype C-V-M-N-K haplotype was highly dominant as well (90%). Our results suggest no immediate concern of maintaining artemisinin and ACTs as first-in-line treatment for malaria in Kongo Central, DRC. However, the findings are of concern and continued molecular surveillance is needed to monitor emerging resistance patterns and allow for a timely response.